Win ratio 法在临床试验中比较两组交叉生存曲线的应用*

张铮 ,  郑思睿 ,  哈艳萍 ,  米白冰 ,  陈方尧 ,  康轶君 ,  裴磊磊

中国卫生统计 ›› 2026, Vol. 43 ›› Issue (3) : 440 -442.

PDF (436KB)
中国卫生统计 ›› 2026, Vol. 43 ›› Issue (3) : 440 -442. DOI: 10.11783/j.issn.1002-3674.2026.03.023
应用研究

Win ratio 法在临床试验中比较两组交叉生存曲线的应用*

作者信息 +

Author information +
文章历史 +
PDF (445K)

摘要

目的 介绍win ratio 方法在解决临床试验中生存曲线交叉问题方面的应用,包括基本原理和应用方法。 方法 以一项临床试验为例,终点事件为肾透析患者发生首次感染,评估传统的外科手术置管与经皮下置管两种方法对 肾透析患者的疗效,使用win ratio 方法,在手术组和经皮组生存曲线互相交叉的情况下,比较两组疗效间的差异。结果 log-rank 检验的P 值为0.11,无法判定疗效优劣。Cox 回归分析的P 值为0.12,由于生存曲线交叉,风险比(hazard ratio, HR)不是恒定值,传统的Cox 回归模型无法应用,结果无意义。win ratio 法分析结果显示,P 值大小为0.01,疗效间差异有 统计学意义。手术置管组发生感染概率约是经皮置管组的3.17倍,即手术置管组的感染发生率较高,95%CI为1.27~7.87。 结论 生存曲线交叉时,log-rank 检验存在偏差,且Cox 模型的比例风险(proportional hazards, PH)假设不成立,win ratio 法不需要假设HR恒定,故win ratio法在检测疗效差异上优于log-rank检验和Cox模型。

关键词

win ratio / 生存曲线交叉 / 生存分析 / 临床试验

Key words

引用本文

引用格式 ▾
张铮,郑思睿,哈艳萍,米白冰,陈方尧,康轶君,裴磊磊. Win ratio 法在临床试验中比较两组交叉生存曲线的应用*[J]. 中国卫生统计, 2026, 43(3): 440-442 DOI:10.11783/j.issn.1002-3674.2026.03.023

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Gregson J, Sharples L, Stone GW, et al. Nonproportional Hazards for Time—to—Event Outcomes in Clinical Trials: JACC Review Topic of the Week [J].J Am Coll Cardiol, 2019, 74(16): 2102-2112.

[2]

Mao L. On the alternative hypotheses for the win ratio [J].Biometrics, 2019, 75(1): 347-351.

[3]

Pocock SJ, Ariti CA, Collier TJ, et al. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities [J].European Heart Journal, 2012, 33(2): 176-182.

[4]

Wang D, Pocock S. A win ratio approach to comparing continuous non—normal outcomes in clinical trials [J].Pharmaceutical Statistics, 2016, 15(3): 238-245.

[5]

Dong G, Hoaglin DC, Qiu J, et al. The win ratio: On Interpretation and Handling of Ties [J].Statistics in Biopharmaceutical Research, 2020, 12(1): 99-106.

[6]

Gasparyan SB, Folkvaljon F, Bengtsson O, et al. Adjusted win ratio with stratification: Calculation methods and interpretation [J].Stat Methods Med Res, 2021, 30(2): 580-611.

[7]

Nahman NS Jr, Middendorf DF, Bay WH, et al. Modification of the percutaneous approach to peritoneal dialysis catheter placement under peritoneoscopic visualization clinical results in 78 patients [J].J Am Soc Nephrol, 1992, 3(1) 103-107.

[8]

Koziol JA, Jia Z, Xia X. Weighted Lin—Wang Tests for Crossing Hazards [J].Computational and Mathematical Methods in Medicine, 2014, 2014: 643455-643457.

[9]

Lin X, Xu Q. A new method for the comparison of survival distributions [J].Pharm Stat, 2010, 9(1): 67-76.

[10]

Lin RS, Leon LF. Estimation of treatment effects in weighted log—rank tests [J].Contemporary Clinical Trials, 2017, 8: 147-155.

[11]

Ratitch B, Goel N, Mallinckrodt C, et al. Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) Guidelines [J].Ther Innov Regul Sci, 2020, 54(2): 370-384.

[12]

Ferreira JP, Jhund PS, Duarte K, et al. Use of the winratio in Cardiovascular Trials [J].JACC Heart Failure, 2020, 8(6): 441-450.

[13]

Fergusson NA, Ramsay T, Chassé M, et al. The win ratio approach did not alter study conclusions and may mitigate concerns regarding unequal composite end points in kidney transplant trials [J].Journal of Clinical Epidemiology, 2018, 98:9-15.

[14]

Kandzari DE, Hickey GL, Pocock SJ, et al. Prioritised endpoints for device—based hypertension trials: the win ratio methodology [J].EuroIntervention, 2021, 16(18): e1496-e1502.

[15]

Zheng S, Wang D, Qiu J, et al. A win ratio approach for comparing crossing survival curves in clinical trials [J].Journal of Biopharmaceutical Statistics, 2023, 33(4): 488-501.

[16]

Dong G, Huang B, Wang D, et al. Adjusting win statistics for dependent censoring [J].Pharm Stat, 2021, 20(3): 440-450.

[17]

Butler J, Stockbridge N, Packer M. Win ratio: A Seductive But Potentially Misleading Method for Evaluating Evidence from Clinical Trials [J].Circulation, 2024, 149(20): 1546-1548.

基金资助

国家自然科学基金(72174167)

AI Summary AI Mindmap
PDF (436KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉